Pushing Boundaries in Nitrosamines Analysis: Spotlight on Nitroso Drug Substance-Related Impurities
Information
The global alert on nitrosamines has profoundly impacted the pharmaceutical industry, necessitating an immediate and comprehensive response from all stakeholders involved. Nitrosamines, which are classified as probable human carcinogens, have historically been associated with the consumption of cured meats and tobacco products, but their unexpected presence in pharmaceuticals prompted a swift reaction from health authorities worldwide.
In response to the global nitrosamine alert, Mérieux NutriSciences' Pharmaceutical and R&D Divisions have utilized their extensive expertise to develop advanced methodologies to tackle the challenges posed by nitrosamine impurities. Drawing on a strong background in the chemical industries, their experts have pioneered the use of sophisticated mass spectrometry technologies to improve the detection and quantification of nitrosamines in drug products, aiding pharmaceutical companies in compliance efforts.
This year, Sergio Fasan, Business Director will present all the latest research and innovation in our pharmaceutical labs:
- NDSRIs emerging issues
- Analytical challenges during method development and QC tests on NDSRIs
- Case studies from MxNS Pharma Nitrosamines Labs
